Practical worked examples of application forms and supporting documentation for IDATEN change control plan confirmation applications specific to SaMD. Illustrates how to describe proposed changes, set acceptance criteria, and prepare draft revised approval documents. Issued concurrently with the consolidated Q&A revision.

Consolidated revision of Q&A guidance on the IDATEN change control plan confirmation system, integrating three previously separate documents. Adds provisions specific to AI/ML-enabled medical devices and SaMD, requiring submission of procedures for developing and implementing the change control plan and materials for appropriate AI technology management. Reflects startup company needs and accumulated regulatory experience since the system's 2020 launch.

Q&A addressing application and conformance assessment of Essential Principles Article 12(3). Covers transition period marketing approval application handling, submission documentation methods, third-party agency utilization for JIS T 81001-5-1 conformance, and reliability document review scope. References related MHLW regulatory notices issued in March and May 2023.

Practical guidance on expedited regulatory approval for SaMD including two-stage approval processes. Clarifies early marketing approval application handling across different development stages while maintaining consistent pre- and post-market safety/effectiveness assurance. Developed through public-private-academic collaboration as part of DASH for SaMD strategy, applicable to AI/ML-enabled SaMD.

Notice specifying concrete compliance assessment considerations for Essential Principles Article 12(3). Details additional verification items against JIS T 81001-5-1 provisions (general requirements, maintenance processes, configuration management). Requires demonstration of intended use environment through system/network architecture diagrams and integration of vulnerability notification activities into quality management systems.

Revision of 2021 SaMD classification guideline (2023 version). Clarifies and refines classification criteria based on accumulated consultation cases. Adds judgment criteria for AI/ML-enabled software, cloud-based programs, and wellness applications. Maintains alignment with IMDRF N10 and N12. Updates judgment flow based on intended use and risk.

MHLW notification of Cybersecurity Guideline for healthcare facility administrators and staff. Presents practical procedures for information collection from manufacturers, risk assessment, pre-implementation verification, vulnerability response during operation, and EOL management. Positioned as the healthcare facility counterpart to the related manufacturer-directed guideline, structured to promote coordination between both parties.

MHLW notification of revised Cybersecurity Guideline for Medical Device Manufacturers (2nd Edition). Updated to align with Essential Principles Article 12(3) implementation. Provides practical procedures for security requirements identification, architecture design, SBOM, PSIRT establishment, and vulnerability disclosure. Functions as specific guidance for JIS T 81001-5-1 application.

Interpretation notice accompanying April 1, 2023 enforcement of Essential Principles Article 12(3) cybersecurity requirements. Mandates three elements for network-connected medical devices: lifecycle cybersecurity planning, risk reduction design, and minimum operational environment specifications. Recognizes JIS T 81001-5-1 conformance as equivalent to Article 12(3) compliance. Provides transition period until March 31, 2024.

Foundational notification establishing Japan's IDATEN system (Improvement Design within Approval for Timely Evaluation and Notice). Defines the scope of eligible changes, application form requirements, supporting documentation, and notification procedures for implementing changes under a confirmed plan. Enables AI-enabled SaMD and other devices with anticipated post-market improvements to implement changes via minor change notification rather than full partial change approval.